Sanofi is being pro-active in expanding its horizons, it hails notable key partnerships and acquisitions.
Sanofi CSO Frank Nestle leaves the company for Deerfield, while the company makes news with a β¬20bn consumer healthcare spin-off. Significant partnerships have been initiated with
OpenAI, Formation Bio, and
Novavax, pivoting towards AI-driven drug development & commercialization of Covid vaccines. The impact of the Sanofi-Novavax deal was major, nearly doubling Novavax's stock valuation. The company stays engaged in persistent research, with the Sarclisa aimed to overthrow J&J's dominance in multiple myeloma treatment. Sanofi takes responsible steps to replace animals with virtual controls in preclinical research. Meanwhile,
Sanofi has faced a blow after
FDA delays a decision on their Dupixent for COPD, which incurred a significant financial loss in a
Hawaii Plavix case. Interestingly, Sanofi looks to fortify its role in the
global health arena, particularly in low- and middle-income nations. EMA also backs approving Sanofi's Dupixent for 'smoker's lungs. Other notable highlights include Sanofi's investment in French production sites, its profit affected by generic competition and currency effects, and a focus on undruggable targets in immunology.
Sanofi News Analytics from Fri, 01 Sep 2023 23:17:18 GMT to Fri, 07 Jun 2024 12:30:00 GMT -
Rating -2
- Innovation 3
- Information 7
- Rumor -3